- Home
- NRXS vs LIXT Comparison
NRXS vs LIXT Comparison
Compare NRXS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- LIXT
- Stock Information
- Founded
- NRXS 2011
- LIXT 2005
- Country
- NRXS United States
- LIXT United States
- Employees
- NRXS N/A
- LIXT N/A
- Industry
- NRXS
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- LIXT Health Care
- Exchange
- NRXS Nasdaq
- LIXT Nasdaq
- Market Cap
- NRXS 13.0M
- LIXT 12.4M
- IPO Year
- NRXS 2023
- LIXT N/A
- Fundamental
- Price
- NRXS $2.41
- LIXT $3.59
- Analyst Decision
- NRXS Strong Buy
- LIXT
- Analyst Count
- NRXS 1
- LIXT 0
- Target Price
- NRXS $7.00
- LIXT N/A
- AVG Volume (30 Days)
- NRXS 55.7K
- LIXT 151.4K
- Earning Date
- NRXS 08-12-2025
- LIXT 08-07-2025
- Dividend Yield
- NRXS N/A
- LIXT N/A
- EPS Growth
- NRXS N/A
- LIXT N/A
- EPS
- NRXS N/A
- LIXT N/A
- Revenue
- NRXS $3,217,531.00
- LIXT N/A
- Revenue This Year
- NRXS $73.05
- LIXT N/A
- Revenue Next Year
- NRXS $130.42
- LIXT N/A
- P/E Ratio
- NRXS N/A
- LIXT N/A
- Revenue Growth
- NRXS 41.93
- LIXT N/A
- 52 Week Low
- NRXS $1.33
- LIXT $0.64
- 52 Week High
- NRXS $6.20
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- NRXS 42.66
- LIXT 45.72
- Support Level
- NRXS $2.26
- LIXT $3.38
- Resistance Level
- NRXS $2.57
- LIXT $4.90
- Average True Range (ATR)
- NRXS 0.14
- LIXT 0.53
- MACD
- NRXS -0.02
- LIXT -0.18
- Stochastic Oscillator
- NRXS 37.94
- LIXT 11.93
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.